Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga, Mark X. Sliwkowski, C. Kent Osborne et al. · Nature Reviews Clinical Oncology · 2011
Cited by 861 works. doi:10.1038/nrclinonc.2011.177
Authors
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
- Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
- Untangling the ErbB signalling network
- Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
- Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
- USE OF CHEMOTHERAPY PLUS A MONOCLONAL ANTIBODY AGAINST HER2 FOR METASTATIC BREAST CANCER THAT OVEREXPRESSES HER2
- Adjuvant Trastuzumab in HER2-Positive Breast Cancer